| Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia DL Rolnik, D Wright, LC Poon, N O’Gorman, A Syngelaki, ... New England Journal of Medicine 377 (7), 613-622, 2017 | 2020 | 2017 |
| Competing risks model in early screening for preeclampsia by biophysical and biochemical markers R Akolekar, A Syngelaki, L Poon, D Wright, KH Nicolaides Fetal diagnosis and therapy 33 (1), 8-15, 2013 | 712 | 2013 |
| Prediction of early, intermediate and late pre‐eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks R Akolekar, A Syngelaki, R Sarquis, M Zvanca, KH Nicolaides Prenatal diagnosis 31 (1), 66-74, 2011 | 698 | 2011 |
| Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation N O’Gorman, D Wright, A Syngelaki, R Akolekar, A Wright, LC Poon, ... American journal of obstetrics and gynecology 214 (1), 103. e1-103. e12, 2016 | 634 | 2016 |
| Challenges in the diagnosis of fetal non‐chromosomal abnormalities at 11–13 weeks A Syngelaki, T Chelemen, T Dagklis, L Allan, KH Nicolaides Prenatal diagnosis 31 (1), 90-102, 2011 | 593 | 2011 |
| Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population KH Nicolaides, A Syngelaki, G Ashoor, C Birdir, G Touzet American journal of obstetrics and gynecology 207 (5), 374. e1-374. e6, 2012 | 578 | 2012 |
| Maternal age and adverse pregnancy outcome: a cohort study A Khalil, A Syngelaki, N Maiz, Y Zinevich, KH Nicolaides Ultrasound in Obstetrics & Gynecology 42 (6), 634-643, 2013 | 558 | 2013 |
| Fetal fraction in maternal plasma cell‐free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics G Ashoor, A Syngelaki, LCY Poon, JC Rezende, KH Nicolaides Ultrasound in Obstetrics & Gynecology 41 (1), 26-32, 2013 | 552 | 2013 |
| Competing risks model in screening for preeclampsia by maternal characteristics and medical history D Wright, A Syngelaki, R Akolekar, LC Poon, KH Nicolaides American journal of obstetrics and gynecology 213 (1), 62. e1-62. e10, 2015 | 468 | 2015 |
| ASPRE trial: performance of screening for preterm pre‐eclampsia DL Rolnik, D Wright, LCY Poon, A Syngelaki, N O'Gorman, ... Ultrasound in obstetrics & gynecology 50 (4), 492-495, 2017 | 457 | 2017 |
| Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18 G Ashoor, A Syngelaki, M Wagner, C Birdir, KH Nicolaides American journal of obstetrics and gynecology 206 (4), 322. e1-322. e5, 2012 | 452 | 2012 |
| Multicenter screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations N O'Gorman, D Wright, LC Poon, DL Rolnik, A Syngelaki, ... Ultrasound in Obstetrics & Gynecology 49 (6), 756-760, 2017 | 391 | 2017 |
| Validation of targeted sequencing of single‐nucleotide polymorphisms for non‐invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y KH Nicolaides, A Syngelaki, M Gil, V Atanasova, D Markova Prenatal diagnosis 33 (6), 575-579, 2013 | 370 | 2013 |
| Metformin versus placebo in obese pregnant women without diabetes mellitus A Syngelaki, KH Nicolaides, J Balani, S Hyer, R Akolekar, R Kotecha, ... New England Journal of Medicine 374 (5), 434-443, 2016 | 340 | 2016 |
| Screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation MY Tan, A Syngelaki, LC Poon, DL Rolnik, N O'Gorman, JL Delgado, ... Ultrasound in Obstetrics & Gynecology 52 (2), 186-195, 2018 | 335 | 2018 |
| Comparison of diagnostic accuracy of early screening for pre‐eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE MY Tan, D Wright, A Syngelaki, R Akolekar, S Cicero, D Janga, M Singh, ... Ultrasound in Obstetrics & Gynecology 51 (6), 743-750, 2018 | 322 | 2018 |
| A competing risks model in early screening for preeclampsia D Wright, R Akolekar, A Syngelaki, LCY Poon, KH Nicolaides Fetal diagnosis and therapy 32 (3), 171-178, 2012 | 313 | 2012 |
| Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks S Nanda, M Savvidou, A Syngelaki, R Akolekar, KH Nicolaides Prenatal diagnosis 31 (2), 135-141, 2011 | 293 | 2011 |
| Accuracy of competing‐risks model in screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation N O'Gorman, D Wright, LC Poon, DL Rolnik, A Syngelaki, A Wright, ... Ultrasound in obstetrics & gynecology 49 (6), 751-755, 2017 | 273 | 2017 |
| Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation LCY Poon, NA Zymeri, A Zamprakou, A Syngelaki, KH Nicolaides Fetal diagnosis and therapy 31 (1), 42-48, 2012 | 272 | 2012 |
Professor Ranjit AkolekarConsultant in Fetal Medicine and ObstetricsVerified email at thepregnancyclinic.com
